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ABSTRACT
Context: There is ongoing uncertainty about the optimal
management of patients with localised prostate cancer.
Objective: To evaluate the comparative efficacy and
safety of different treatments for patients with localised
prostate cancer.
Design: Systematic review with Bayesian network meta-
analysis to estimate comparative ORs, and a score
(0–100%) that, for a given outcome, reflects average rank
order of superiority of each treatment compared against
all others, using the Surface Under the Cumulative
RAnking curve (SUCRA) statistic.
Data sources: Electronic searches of MEDLINE without
language restriction.
Study selection: Randomised trials comparing the
efficacy and safety of different primary treatments (48
papers from 21 randomised trials included 7350 men).
Data extraction: 2 reviewers independently extracted
data and assessed risk of bias.
Results: Comparative efficacy and safety evidence was
available for prostatectomy, external beam radiotherapy
(different types and regimens), observational
management and cryotherapy, but not high-intensity
focused ultrasound. There was no evidence of superiority
for any of the compared treatments in respect of all-
cause mortality after 5 years. Cryotherapy was associated
with less gastrointestinal and genitourinary toxicity than
radiotherapy (SUCRA: 99% and 77% for gastrointestinal
and genitourinary toxicity, respectively).
Conclusions: The limited available evidence suggests
that different treatments may be optimal for different
efficacy and safety outcomes. These findings highlight
the importance of informed patient choice and shared
decision-making about treatment modality and
acceptable trade-offs between different outcomes. More
trial evidence is required to reduce uncertainty. Network
meta-analysis may be useful to optimise the power of
evidence synthesis studies once data from new
randomised controlled studies in this field are published
in the future.
BACKGROUND
Prostate cancer is a worldwide major public
health issue.1 Nearly 75% of diagnosed cases,
however, occur in developed countries,2
where it is typically the most common cancer
in men.3 4 In the UK, about 40 000 men are
diagnosed with prostate cancer and 10 000
men die from it every year.3 In the USA, there
are 240 000 new diagnoses of prostate cancer,
with 34 000 associated deaths every year.5
Most patients with prostate cancer are diag-
nosed at an early stage,6 7 and many diagno-
ses are made in asymptomatic men.8–10
The main treatment options for localised
prostate cancer include radical prostatec-
tomy, external beam radiotherapy and obser-
vational management (ie, regular testing of
clinical, biochemical or radiological markers
or as prompted by occurrence of symp-
toms).8 As some of these treatments are asso-
ciated with substantial risk of side effects, it is
important to try to resolve the current uncer-
tainty about the optimal treatment options.
Some randomised trials have compared
the efﬁcacy and safety of two or three treat-
ments. For example, the SPCG-4 trial in
Europe and the PIVOT study in the USA
compared radical prostatectomy with obser-
vational management.11 12 The UK Prostate
Testing for Cancer and Treatment (ProtecT)
Strengths and limitations of this study
▪ Network meta-analysis enabled us to integrate
evidence from direct comparisons (treatments
compared head to head within a randomised
trial) and indirect comparisons (treatments com-
pared by combining the results of randomised
trials with common comparators).
▪ This network meta-analysis only included rando-
mised controlled trials and the risk of bias in
each included study had been comprehensively
assessed by using the Cochrane Collaboration’s
Risk of Bias tool, which strengthens the robust-
ness of evidence synthesis.
▪ The number of available randomised controlled
trials was small which could be a limitation of
the study.
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trial is evaluating treatment effectiveness of active moni-
toring, radical prostatectomy and external beam radio-
therapy for clinically localised prostate cancer in men
aged 50–69 years identiﬁed through population-based
prostate-speciﬁc antigen (PSA) testing.13 The recruit-
ment phase for the ProtecT trial, which began in 1999,
has been completed, but outcomes will not be available
until a minimum follow-up period has been accrued.
It is unlikely that any single trial will compare all avail-
able treatment options. We therefore performed a
network meta-analysis based on a systematic review of
completed randomised trials comparing different inter-
ventions for patients with localised prostate cancer. The
network meta-analysis allowed us to integrate evidence
from direct comparisons (treatments compared head to
head within a randomised trial) and indirect compari-
sons (treatments compared by combining the results of
randomised trials with common comparators).14–16 Our
objective was to apply the established methodology used
in network meta-analysis to an area of clinical practice
where no such previous studies existed. In doing so, our
aims were to summarise existing evidence; ‘map out’
current gaps in comparative evidence to help motivate
the design and conduct of future comparative studies
and develop an approach ‘primed’ for subsequent
updating and incorporation of future trial evidence.
METHODS
Eligibility criteria
We sought completed randomised trials in men with
localised prostate cancer that had compared two or
more of the following interventions (as primary treat-
ment, with or without the same adjuvant therapy in all
arms): prostatectomy, radiotherapy including brachyther-
apy, cryotherapy, high-intensity focused ultrasound
(HIFU) and observational management. Observational
management is characterised by testing of clinical, bio-
chemical or radiological markers of disease progression
at regular intervals (typically every 6 months) or as
prompted by the occurrence of new symptoms, possibly
leading to either radical or palliative treatment. We
opted to use the term ‘observational management’ in
preference to active surveillance or active monitoring
because the latter terms typically aim to keep men in a
window of curability so that only those who require it
undergo radical treatment.
Eligible trials had to have reported any of the follow-
ing efﬁcacy and safety outcomes: all-cause mortality,
prostate cancer mortality and gastrointestinal (GI) or
genitourinary (GU) toxicity. Studies comparing treat-
ment combinations or sequences (eg, per protocol man-
agement by surgery with subsequent radiotherapy) were
excluded.
Identification of studies
We adopted the search strategy of a systematic review
that supported the development of clinical guidelines
on the diagnosis and treatment of prostate cancer by the
UK’s National Institute for Health and Clinical
Excellence (NICE) in 2008.8 Studies had been identiﬁed
by searching MEDLINE (in 2006) and scanning refer-
ence list of papers. We retrieved all relevant randomised
trials identiﬁed in the NICE guidelines and implemen-
ted the same search strategies to update the collection
of trials. We restricted the search to the period from
January 2005 to September 2012. No language limits
were placed on the searches (see online supplementary
appendix 1 for full search strategies).
Data extraction
Two reviewers (TX and RMT) independently screened
all the titles and abstracts of the studies retrieved by the
searches for potentially eligible trials, and then inde-
pendently assessed the full articles of these trials to
conﬁrm whether they met the eligibility criteria. The
results were checked and discussed by TX and RMT to
agree on a ﬁnal list of included studies. Using a struc-
tured and piloted data collection form, all relevant data
in each included paper were extracted by two reviewers
independently (TX and RMT/YW). The data extracted
were cross-checked and unresolved discrepancies were
referred to a third reviewer; where necessary, problems
were discussed in a panel meeting (TX, RMT, YW, JPTH
and GL) while DEN acted as a clinical expert advisor.
For each included study, we extracted characteristics of
participants and interventions, outcomes reported and
collected, sample size (randomised and analysed) in
each arm, numerical results, losses to follow-up and
details of patients excluded from the analyses.17 To
inform the appropriateness of including studies in the
meta-analysis and facilitate assessment of the strength of
the evidence we assessed the risk of bias in each
included study using the Cochrane Collaboration’s Risk
of Bias tool.18 Two reviewers (TX and either RMT or
YW) completed this independently and agreed on ﬁnal
assessments. The tool assesses risk of bias arising from
inadequacies in processes of generation of the random
allocation sequence, concealment of the allocation
sequence and blinding and from incomplete outcome
data and selective outcome reporting.
Outcomes
We analysed all-cause mortality and cancer-related mor-
tality at 5 years, late GI and late GU toxicity at 3 years.
The choice of these follow-up times was pragmatic, as
they were the ones most frequently reported in the
included trials. Once these time points had been
chosen, we extracted the outcome data from the time
nearest to these targeted measurement times. Late GI
and late GU toxicity were deﬁned as scores ≥2 measured
by the Radiation Therapy Oncology Group (RTOG)
questionnaire scale at 3 years follow-up.19 We have not
encompassed biochemical or clinical failure as oper-
ational deﬁnitions of either of those outcomes tend to
be speciﬁc to different radical treatment modalities.20
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Statistical analyses
Initially, we compared each pair of treatments using
direct evidence alone, for each outcome. Separate
meta-analyses were performed for each pair-wise com-
parison of interventions: a random-effects model was
ﬁtted within each comparison,21 with a common
between-study heterogeneity variance assumed across
comparisons to allow for heterogeneity even when only a
single study was available. Results are reported as ORs
with 95% CIs, for every comparison evaluated directly in
one or more studies.
Next, we ﬁtted a network meta-analysis model for each
outcome separately,22 combining direct evidence for
each comparison (eg, from studies comparing interven-
tions A with B) with indirect evidence (eg, from studies
comparing A with C and studies comparing B with C),
for all pair-wise comparisons simultaneously. The model
accounts explicitly for the binary nature of each
outcome using a binomial likelihood function; allows for
heterogeneity of treatment effects between trials of the
same comparison (assuming the same amount of hetero-
geneity for each comparison, irrespective of how many
trials address it) and enforces an underlying relationship
between direct and indirect evidence for a particular
comparison, assuming these are consistent between the
two sources. For each ‘loop’ of treatment comparisons
from three or more independent sources and for each
outcome, we computed the difference between estimates
from direct and indirect evidence on the log OR scale.23
This provides a measure of inconsistency between the
different sources. We did not implement more sophisti-
cated methods for testing or adjusting for inconsistency
due to the small number of loops in the network.
Results are reported as ORs with 95% credible inter-
vals for all pair-wise comparisons of interventions. All
analyses were performed within a Bayesian framework,
using Markov chain Monte Carlo methods in WinBUGS
(MRC Biostatistics Unit, Cambridge, UK).24 Informative
prior distributions were used for the heterogeneity vari-
ance, from a published set of distributions for hetero-
geneity expected in meta-analyses examining particular
intervention and outcome types,25 since heterogeneity is
imprecisely estimated when the number of studies is
small. For all-cause mortality, a log-normal (−3.93, 1.512)
distribution was used. For GI and GU toxicity, a
log-normal (−2.01, 1.642) distribution was used. For
cancer-related mortality, a log-normal (−2.89, 1.912) distri-
bution was used. Vague N (0, 104) priors were used for all
other model parameters. Results were based on 100 000
iterations, following a burn-in of 20 000 iterations.
For each outcome, we estimated the probability that
each intervention is superior to all others, the second best,
the third best and so on, from the rank orderings of the
treatments at each iteration of the Markov chain. These
ranking probabilities were used to calculate a summary
numerical value: the Surface Under the Cumulative
RAnking curve (SUCRA).26 SUCRA values are expressed
as percentages; if an intervention is certainly the best, its
SUCRA value would be 100%, and if an intervention is cer-
tainly the worst, its SUCRA value would be 0%. If all inter-
ventions are equivalent, we would expect all SUCRA values
to be near 50%. We also report the median ranks and
95% credible intervals for each intervention.
RESULTS
Included studies and interventions
The NICE systematic review8 had identiﬁed 20 reports
relating to 14 randomised trials.27–46 Our updated
searches retrieved 1740 studies and identiﬁed 39 reports
of relevant randomised trials, of which 30 had not been
included in the NICE review (ﬁgure 1).47–76 One of these
reports was the sole report of a trial providing data only
on acute toxicity,41 one paper reported only clinical
failure39 and one paper reported biochemical failure,
biochemical disease-free survival and quality of life57;
these three studies were then excluded since they did not
report the outcomes of interest to us. In addition to the
remaining 47 full papers from peer-reviewed journals, we
identiﬁed and included in the analysis data from a con-
ference abstract, describing a randomised trial compar-
ing external beam radiotherapy versus watchful waiting,77
and reporting data on long-term mortality not previously
reported in full-text-related publications.78 79
Our searches also identiﬁed 16 relevant systematic
reviews.80–95 We scrutinised the reference lists of all
these as well as any further systematic reviews identiﬁed
by the NICE review, and found no further relevant ran-
domised trials.
The 48 identiﬁed reports described 21 randomised
trials comparing the effectiveness of different treatments
for localised prostate cancer.27–38 40 42–56 58–77 Seventeen
trials reported all-cause mortality, 16 trials reported
cancer-related mortality, 16 trials reported GI toxicity, 15
trials reported GU toxicity. The characteristics of
included studies are summarised in online supplemen-
tary appendix 2.
The risk of bias assessments for the included trials is
illustrated in ﬁgure 2. Most of the evidence was of
moderate-to-good quality. About half of the studies did
not report adequate information about allocation
sequence generation and allocation sequence conceal-
ment. Unblinded designs were used in all trials
included; we judged this unlikely to cause bias for
objectively measured outcomes such as mortality, but
generate bias in the reporting and assessment of patient-
reported toxicity outcomes. The small number of studies
precluded the investigation of potential reporting biases
across studies (eg,using funnel plots). Our searches were
appropriate, but the possibility of publication bias
cannot be excluded. It is unclear, however, whether
reporting biases would tend to favour any particular
treatment (see online supplementary appendix 3 for
details of bias assessments for included trials).
We categorised the interventions into the following
eight categories: observational management,
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prostatectomy, conventional radiotherapy (refers to two-
dimensional external beam radiation therapy), conven-
tional radiotherapy hypofractionated (refers to less than
20 fractions), conformal low dose (LD) radiotherapy
(refers to less than 68 Gy), conformal high dose (HD)
radiotherapy (refers to more than 74 Gy), conformal LD
radiotherapy hypofractionated and cryotherapy. Twenty
trials had two intervention arms. One trial compared
three interventions55; since two of the three interven-
tions were very similar and both met our deﬁnition of
conformal LD radiotherapy hypofractionated, we com-
bined the data from these two arms and regarded the
trial as a two-treatment comparison (conformal LD
radiotherapy hypofractionated vs conformal HD radio-
therapy). None of the reviewed studied assessed brachy-
therapy and HIFU. Figure 3 illustrates the full network
of comparisons. There were two closed loops of compar-
isons, one connecting prostatectomy, observational man-
agement and radiotherapy modalities; and the other
connecting different radiotherapy modalities.23 No
inconsistency was detected in our estimates of the differ-
ence between direct and indirect evidence; however,
precision was very low. Cryotherapy only had a single
link to the network.
All-cause mortality
All-cause mortality was reported in 17 trials, covering all
the eight interventions of interest. There is no evidence of
superiority of any treatment for all-cause mortality. For
each pair-wise comparison of interventions, the 95% inter-
vals for ORs were wide and included 1. The lower-left tri-
angle of results in table 1 presents ORs estimated from
direct evidence alone, while the upper-right triangle of
results presents ORs estimated from the network
meta-analysis. The intervals are slightly narrower when
based on indirect as well as direct evidence rather than
direct evidence alone. The SUCRA values presented in
table 2 summarise the ranking information for all inter-
ventions. With respect to all-cause mortality, the highest
SUCRA values are 69% for conformal LD radiotehrapy
hypofractionated and 63% for conformal HD radiother-
apy, indicating that these are most likely to be among the
best treatments for this outcome. However, there is very
Figure 1 Flowchart of the inclusion process of the studies for network meta-analysis.
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high uncertainty in the rankings of the interventions, as
indicated by wide 95% credible intervals.
Cancer-related mortality
Cancer-related mortality was reported in 16 trials, covering
eight of the interventions. This was a rare outcome in
most treatment groups, as expected for patients with loca-
lised prostate cancer with a 5-year end point. OR estimates
had wide 95% credible intervals, particularly in compari-
son for which only indirect evidence was available, and
there was no evidence of superiority for any of the com-
parator treatments (table 3). Based on direct comparisons
alone, conformal HD radiotherapy was superior to conven-
tional radiotherapy (OR 0.21 (95% interval 0.03 to 0.97))
and prostatectomy was superior to observational manage-
ment (OR 0.60 (95% interval 0.37 to 0.98)).
GI and GU toxicity
Late GI toxicity was reported in 16 trials and late GU
toxicity was reported in 15 trials. There was evidence
Figure 2 Risk of bias assessments for the included randomised trials.
Figure 3 Network of comparisons of treatments for localised
prostate cancer, showing numbers of trials in which each
pair-wise comparison had been made.
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Table 1 All-cause mortality: ORs (posterior mean with 95% intervals) for each pair-wise comparison of interventions, based on direct evidence alone (lower-left triangle) or direct and indirect
evidence (upper-right triangle)
Intervention
Observational
management Prostatectomy
Conventional
radiotherapy
Conventional
radiotherapy
hypofractionated
Conformal LD
radiotherapy
Conformal HD
radiotherapy
Conformal LD
radiotherapy
hypofractionated Cryotherapy
Observational management 0.79 (0.61,1.02) 0.84 (0.48,1.57) 0.72 (0.37,1.49) 0.73 (0.44,1.26) 0.70 (0.40,1.28) 0.53 (0.10,2.88) 0.76 (0.28,1.98)
Prostatectomy 3 0.80 (0.61,1.06) 1.06 (0.60,2.02) 0.91 (0.46,1.90) 0.92 (0.54,1.64) 0.88 (0.49,1.66) 0.67 (0.12,3.65) 0.96 (0.36,2.56)
Conventional radiotherapy – 1 1.34 (0.55,3.24) 0.85 (0.59,1.24) 0.86 (0.55,1.35) 0.82 (0.51,1.35) 0.62 (0.11,3.21) 0.90 (0.41,1.89)
Conventional radiotherapy hypofractionated – – 2 0.85 (0.59,1.24) 1.01 (0.56,1.80) 0.97 (0.53,1.78) 0.73 (0.13,3.86) 1.05 (0.44,2.42)
Conformal LD radiotherapy 1 0.66 (0.35,1.21) – 1 0.92 (0.50,1.72) – 0.96 (0.72,1.29) 0.72 (0.14,3.51) 1.04 (0.42,2.49)
Conformal HD radiotherapy – – 1 0.87 (0.39,1.92) – 4 0.95 (0.70,1.31) 0.74 (0.14,3.61) 1.09 (0.43,2.64)
Conformal LD radiotherapy hypofractionated – – – – – 2 0.78 (0.13,4.25) 1.47 (0.22,9.40)
Cryotherapy – – 2 0.90 (0.41,2.02) – – – –
Lower-left results compare row-defining interventions against column-defining interventions. Upper-right results compare column-defining interventions against row-defining interventions.
In the meta-analysis of direct comparisons (reported in lower-left triangle), between-trial heterogeneity τ² was estimated as 0.009 (95% interval 0.001 to 0.08).
In the network meta-analysis (reported in upper-right triangle), between-trial heterogeneity τ² was estimated as 0.009 (95% interval 0.001 to 0.07).
The small superscript numbers in the cells of lower-left triangle indicate the numbers of randomised trials which compared the two interventions directly.
HD, high dose; LD, low dose.
Table 2 Ranking of interventions with respect to all-cause and cancer-related mortality, adverse gastrointestinal and genitourinary events: SUCRA values and median
ranks (with 95% intervals)*
Intervention
All-cause mortality Cancer-related mortality
Adverse gastrointestinal
events Adverse genitourinary events
SUCRA
value (%)
Median rank
(95% interval)
SUCRA
value (%)
Median rank
(95% interval)
SUCRA
value (%)
Median rank
(95% interval)
SUCRA
value (%)
Median rank
(95% interval)
Observational management 18 7 (2 to 8) 30 6 (3 to 8) – – – –
Prostatectomy 49 5 (1 to 7) 64 4 (1 to 7) – – – –
Conventional radiotherapy 35 6 (2 to 8) 16 7 (4 to 8) 43 4 (2 to 6) 51 3 (1 to 6)
Conventional radiotherapy
hypofractionated
58 4 (1 to 8) 44 5 (1 to 8) 42 4 (1 to 6) 50 3 (1 to 6)
Conformal LD radiotherapy 57 4 (1 to 7) 61 4 (2 to 7) 67 2 (2 to 4) 66 3 (1 to 5)
Conformal HD radiotherapy 63 3 (1 to 7) 75 2 (1 to 6) 19 5 (3 to 6) 30 5 (2 to 6)
Conformal LD radiotherapy
hypofractionated
69 1 (1 to 8) 85 1 (1 to 8) 30 5 (2 to 6) 26 5 (1 to 6)
Cryotherapy 50 4 (1 to 8) 24 7 (2 to 8) 99 1 (1 to 2) 77 1 (1 to 6)
*The SUCRA value is a numerical summary of the estimated probabilities that each treatment is the best, second best, third best (and so on) for that particular outcome. Higher values indicate
higher rankings compared with other treatments. For example, for cryotherapy, the high SUCRA value of 99% and median rank of 1 for adverse gastrointestinal events shows that cryotherapy is
expected to be superior with respect to this outcome.
HD, high dose; LD, low dose; SUCRA, Surface Under the Cumulative RAnking curve.
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that cryotherapy resulted in fewer adverse GI events
than radiotherapy treatments (estimated ORs comparing
cryotherapy against the ﬁve radiotherapy options ranged
from 0.12 to 0.24, while all but one of the respective
95% credible intervals excluded 1). The SUCRA value of
99% for cryotherapy and the median rank of 1 (95%
interval 1, 2) suggest that cryotherapy is almost certainly
superior among the six treatments included in the
network meta-analysis in relation to adverse GI
events (tables 2 and 4). There was also evidence that
GI toxicity was more likely with conformal HD radiother-
apy than with conformal LD radiotherapy.
Interpretation of such ﬁndings for toxicity should be
more cautious than for the other outcomes, due to a
concern that lack of blinding could have led to a risk of
detection bias. For GU toxicity, there was no evidence
favouring one intervention over another (table 5),
although cryotherapy tended to receive better rankings
than the ﬁve radiotherapy treatments (table 2), and the
OR estimates favour cryotherapy, but the 95% intervals
all included 1.
DISCUSSION
Using network meta-analysis, we were able to combine
simultaneously all relevant evidence on treating patients
with localised prostate cancer, even in the absence of
direct comparative evidence for some treatment pairs,
encompassing four efﬁcacy and safety outcomes. Based
on data from 21 trials including 7350 patients randomly
assigned among eight different intervention regimes for
localised prostate cancer, we found substantial uncer-
tainty about the relative efﬁcacy and safety of different
interventions in respect of the studied outcomes.
Assumptions of consistency between direct and indir-
ect evidence were tested to justify the joint synthesis of
all studies; however, these tests had little power due to
the relatively small number of trials available in most
direct comparisons. Instead we must rely on judgements
about the similarity of studies included in the analysis in
aspects such as patient groups, outcome measures and
study methodology. Although we deﬁned the population
of interest as patients with localised prostate cancer,
there was heterogeneity between individual study popu-
lations in terms of the severity of disease. Some of the
trials were conducted several decades ago, when surgery
and radiology techniques may have been different, and
we observed that stage migration has occurred in men
diagnosed with prostate cancer due to emerging bio-
marker and image technologies. Furthermore, some of
the trials used adjuvant therapy, although this was
applied in all the arms within the trial.
Two further limitations warrant mention. Literature
searches were completed in September of 2012.
However, the results of one of the most important ran-
domised trials—ProtecT study13—has not been pub-
lished so far, and to our knowledge no other new
relevant randomised controlled trials (RCTs) have been
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Table 4 Adverse gastrointestinal events: ORs (posterior mean with 95% intervals) for each pair-wise comparison of interventions, based on direct evidence alone (lower-left triangle) or direct
and indirect evidence (upper-right triangle)
Intervention
Observational
management Prostatectomy
Conventional
radiotherapy
Conventional
radiotherapy
hypofractionated
Conformal LD
radiotherapy
Conformal HD
radiotherapy
Conformal LD
radiotherapy
hypofractionated Cryotherapy
Observational management – – – – – – –
Prostatectomy 2 0.84 (0.33,1.88) – – – – – –
Conventional radiotherapy – – 1.01 (0.19,5.29) 0.72 (0.29,1.59) 1.42 (0.57,3.39) 1.26 (0.35,4.30) 0.17 (0.04,0.51)
Conventional radiotherapy hypofractionated – – 1 1.00 (0.22,4.56) 0.70 (0.11,4.37) 1.40 (0.21,9.02) 1.24 (0.15,9.76) 0.17 (0.02,1.19)
Conformal LD radiotherapy – – 2 0.46 (0.17,1.16) – 1.98 (1.18,3.59) 1.77 (0.63,5.11) 0.24 (0.05,0.96)
Conformal HD radiotherapy – – 1 2.66 (0.85,8.62) – 5 1.73 (1.07,2.97) 0.89 (0.36,2.15) 0.12 (0.02,0.48)
Conformal LD radiotherapy hypofractionated – – – – – 3 0.89 (0.39,1.96) 0.14 (0.02,0.70)
Cryotherapy – – 2 0.18 (0.05,0.50) – – – –
Lower-left results compare row-defining interventions against column-defining interventions. Upper-right results compare column-defining interventions against row-defining interventions.
The comparison of prostatectomy with observational management was not linked to the rest of the network, so this evidence was included in the meta-analysis of direct comparisons only.
In the meta-analysis of direct comparisons (reported in lower-left triangle), between-trial heterogeneity τ² was estimated as 0.14 (95% interval 0.01 to 0.97).In the network meta-analysis (reported
in upper-right triangle), between-trial heterogeneity τ² was estimated as 0.24 (95% interval 0.02 to 1.23).
The small superscript numbers in the cells of lower-left triangle indicate the numbers of randomised trials which compared the two interventions directly.
HD, high dose; LD, low dose.
Table 5 Adverse genitourinary events: ORs (posterior mean with 95% intervals) for each pair-wise comparison of interventions, based on direct evidence alone (lower-left triangle) or direct and
indirect evidence (upper-right triangle)
Intervention
Observational
management Prostatectomy
Conventional
radiotherapy
Conventional
radiotherapy
hypofractionated
Conformal LD
radiotherapy
Conformal HD
radiotherapy
Conformal LD
radiotherapy
hypofractionated Cryotherapy
Observational management – – – – – – –
Prostatectomy 2 2.27 (1.34,3.90) – – – – – –
Conventional radiotherapy – – 1.00 (0.34,2.90) 0.91 (0.54,1.51) 1.19 (0.69,2.11) 1.41 (0.49,4.07) 0.66 (0.22,2.00)
Conventional radiotherapy hypofractionated – – 1 1.01 (0.34,3.00) 0.90 (0.27,2.97) 1.19 (0.36,4.04) 1.41 (0.31,6.44) 0.66 (0.14,3.04)
Conformal LD radiotherapy – – 2 0.80 (0.43,1.51) – 1.32 (0.97,1.86) 1.56 (0.61,4.09) 0.73 (0.21,2.52)
Conformal HD radiotherapy – – 1 1.53 (0.62,3.82) – 5 1.28 (0.93,1.86) 1.18 (0.48,2.92) 0.55 (0.16,1.91)
Conformal LD radiotherapy hypofractionated – – – – – 2 1.17 (0.48,2.91) 0.47 (0.10,2.15)
Cryotherapy – – 2 0.68 (0.22,2.03) – – – –
Lower-left results compare row-defining interventions against column-defining interventions. Upper-right results compare column-defining interventions against row-defining interventions.
The comparison of prostatectomy with observational management was not linked to the rest of the network, so this evidence was included in the meta-analysis of direct comparisons only.
In the meta-analysis of direct comparisons (reported in lower-left triangle), between-trial heterogeneity τ² was estimated as 0.04 (95% interval 0.003 to 0.29).In the network meta-analysis
(reported in upper-right triangle), between-trial heterogeneity τ² was estimated as 0.04 (95% interval 0.002 to 0.26).
The small superscript numbers in the cells of lower-left triangle indicate the numbers of randomised trials which compared the two interventions directly.
HD, high dose; LD, low dose.
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reported after this systematic review. Our choices of
measurements may have favoured some treatments over
others: for example, the RTOG scale had been used
to deﬁne the late GI and late GU toxicity in the
included studies, but it does not measure incontinence
which could be the most common adverse event
postprostatectomy.96
Methodologically, we used informative prior distribu-
tions based on external evidence for heterogeneity var-
iances to increase precision in their estimation and
improve estimation of treatment differences. Data-based
informative priors have previously been considered by
Lu and Ades,97 who used them for the between-study
correlation structure. To our knowledge, our paper is
the ﬁrst application of network meta-analysis incorporat-
ing data-based informative priors for between-study
heterogeneity.
Our ﬁndings have implications for research funding
prioritisation and study design, and for clinical practice.
The study identiﬁed particular ‘weak links’ in the
network of comparative treatment options, which might
be prioritised for future investment in RCTs. This is par-
ticularly the case for studies comparing HIFU (which cur-
rently is bereft of any comparative evidence) or
brachytherapy against other treatment options, and also
for trials examining the comparative efﬁcacy and safety of
prostatecotmy versus conformal radiotherapy modalities.
For clinicians, and for men diagnosed with prostate
cancer, our ﬁndings highlight that the optimal treatment
options may be different in respect of different outcomes:
patients need to be given appropriate information about
the uncertainty surrounding treatment choice currently,
and be allowed to opt for ‘trade-offs’ between efﬁcacy
and safety outcomes as they judge appropriately.98
Observational studies have consistently shown that radical
prostatectomy has better cause-speciﬁc mortality out-
comes compared with radiotherapy.99–103
In conclusion, clinically important information from
high-quality randomised trials is still needed to inform
decision-making regarding primary treatment options
for men with localised prostate cancer. The ﬁndings of
this study highlight the importance of informed patient
choice and shared decision-making about treatment
modality and acceptable trade-offs between multiple out-
comes. The upcoming results of the ProtecT study,13
which is evaluating effectiveness of multiple therapies in
men with PSA-detected localised prostate cancer,
together with other treatment studies in progress, will
hopefully contribute to the evidence base. It is, however,
unlikely that evidential uncertainty about all relevant
and important outcomes will be resolved by these trials,
and an updated network meta-analysis incorporating
new evidence may be useful to synthesise the new with
the existing evidence. We demonstrate a high degree of
uncertainty about treatment superiority in the manage-
ment of localised prostate cancer. Clinicians and patients
need to grapple with this uncertainty in the context of
shared decision-making.
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